Kodiac program includes two placebo controlled randomized Phase III studies and a randomized, open-label, placebo-controlled long term safety study.
The two studies are designed to investigate the safety, efficacy and tolerability of an experimental drug as a treatment for OIC.
AstraZeneca Clinical Research senior director Jaakko Lappalainen said the Kodiac study is a clinical trial being conducted to help determine whether AstraZeneca’s investigational drug may be helpful in treating this medical problem.